Skip to content

The effect of one month of intermittent fasting on the blood microbiome (OMIF microbiome study) in healthy volunteers

The effect of one month of intermittent fasting on the blood microbiome (OMIF microbiome study) in healthy volunteers - OMIF microbiome study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON57076
Enrollment
48
Registered
2023-12-28
Start date
2025-12-10
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

microbiota microflora microbiota

Interventions

a daily fasting from 7:30 h to 18:30 h for consecutive 30 days

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Age 18-65 years - 18.5 =

Exclusion criteria

Exclusion criteria: - Regular use medications such as antibiotics, steroids, beta blockers, and adrenergic-stimulating agents (self-report). - Regular use prebiotic and/or probiotics (self-report) - Intake of antibiotic at least in previous 1 months (self-report) - Daily consumption of >10 cigarettes, or >6 cups of coffee (self-report) - Chronic disease including type 2 diabetes, hypertension, fatty liver disease, cancer - Autoimmune disease (self-report and blood test) - Internal disease including the gastrointestinal tract, lung, heart, vasculature, liver and kidney (self-report and blood test) - Eating disorder or unconventional eating habits (self-report) - Have a clinically significant abnormality as measured by a blood test - In participation of other study - Habit of performing regular fasting - Women: pregnancy and breastfeeding

Design outcomes

Primary

MeasureTime frame
To explore the effect of OMIF on the blood archaea

Secondary

MeasureTime frame
To explore the effect of OMIF on the blood bacteria. To explore the effect of OMIF on the blood viruses. To explore the relationship between blood and gut microbiome.

Countries

Netherlands

Contacts

Public ContactMP Peppelenbosch

Erasmus MC, Universitair Medisch Centrum Rotterdam

m.peppelenbosch@erasmusmc.nl+31 107032792

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)